Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

ABSTRACT: Immunotherapy acquired resistance was observed in clinical practice. The investigators intended to add anlotinib to PD-1 inhibitors, hoping reverse the resistance.

DISEASE(S): Rectal Neoplasms,Gastric Cancer,Colo-rectal Cancer,Stomach Neoplasms

PROVIDER: 2369106 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR